Table 2.

Overview of clinical and parasitological parameters assessed for volunteer 2

	Study enrolment	Routine visit 1	Routine visit 2	qPCR results reported	Post-treatment visit 1	Post-treatment visit 2
Timeline
Date	22/12/2015	13/02/2016	13/04/2016	28/04/2016	06/05/2016	01/07/2016
Days respective to enrolment into clinical trial	0	53	113	128	136	192
Clinical evaluation
Body temperature	36.5 °C	36.8 °C	36.7 °C	36.6 °C	–	36.4 °C
Vital signs including pulse, blood pressure and respiration rate	NAD	NAD	NAD	NAD	–	NAD
Laboratory evaluation
Biochemistry including ALT, AST	NAD, also included BIL and CRE at enrolment	NAD	NAD	NAD	–	NAD
Complete blood count includes RBC, HGB, HCT, MCV, MCH, MCHC, PLT, WBC with differential	EO ↑ (1.19 × 103/µL, 18.1%)	EO ↑ (1.04 × 103/µL, 17.2%)	EO ↑ (1.06 × 103/µL, 12.0%) RDW-SD ↓ (34.4 fL)	EO ↑ (0.63 × 103/µL, 6.5%) WBC ↑ (9.65 × 103/µL) NEUT ↑ (6.07 × 103/µL, 62.9%)	–	EO ↑ (0.77 × 103/µL, 12.0%) RDW-SD ↓ (33.6 fL)
Urine analysis using dipstick that includes bilirubin, ketone, creatinine, hematuria, proteinuria, albumin, nitrite, leucocytes, glucose, specific gravity, pH, vitamin C	NAD	NAD	NAD	NAD	–	Proteinuria (trace)
Serology (HIV, HBV, HCV)	Negative	–	–	–	–	–
Screening for intestinal helminths and schistosomiasis	Negative	–	–	–	–	–
Malaria diagnostics
Thick blood smear microscopy	Negative	Negative	Negative	Negative	Negative	Negative
Screening and species identification qPCR assays	Screening qPCR: Cq of 31.62 ID-qPCR: P. malariae	Screening qPCR: Cq of 32.78 ID-qPCR: P. malariae	Screening qPCR: Cq of 33.44 ID-qPCR: P. malariae	Screening qPCR: Cq of 34.47 ID-qPCR: P. malariae	Screening qPCR: neg	Screening qPCR: neg
Drug treatment
Prescription of drugs throughout the clinical trial	–	–	–	Start of artesunate-amodiaquine based treatment on 02/05/2016	–	–

NAD no abnormalities detected